This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges
by Zacks Equity Research
Nabriva Therapeutics' (NBRV) lefamulin shows non-inferiority to Avelox in a phase III study on community-acquired bacterial pneumonia patients.
Becton, Dickinson (BDX) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) is set to report first-quarter fiscal 2017 earnings results on Feb 2.
Will PerkinElmer (PKI) Disappoint this Earnings Season?
by Zacks Equity Research
PerkinElmer Inc. (PKI) is expected to report fourth-quarter 2016 results on Feb 2, 2017.
Will Baxter International (BAX) Disappoint in Q4 Earnings?
by Zacks Equity Research
Baxter International Inc. (BAX) is scheduled to report fourth-quarter 2016 earnings on Feb 1, before the opening bell.
Henry Schein (HSIC) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Henry Schein, Inc. (HSIC) is expected to report fourth-quarter 2016 financial numbers on Feb 8, before the opening bell.
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
AmerisourceBergen (ABC) Q1 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen Corp. (ABC) is set to report first-quarter fiscal 2017 results on Jan 31, before the opening bell.
Cempra (CEMP): An Off-the-Radar Potential Winner
by Zacks Equity Research
Cempra, Inc. (CEMP). This Medical stock has actually seen estimates rise over the past month
C.R. Bard (BCR) to Report Q4 Earnings: A Surprise in Store?
by Zacks Equity Research
Delving deeper into the fundamentals of C.R. Bard (BCR), let's see how things are shaping up prior to this quarter.
Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Hologic Inc. (HOLX) is slated to report first-quarter fiscal 2017 financial results on Feb 1, after the closing bell.
Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Myriad Genetics, Inc.(MYGN) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.
IDEXX Laboratories (IDXX) Q4 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report fourth-quarter 2016 results on Feb 2, before the opening bell.
Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2.
Edward Lifesciences (EW): What's in Store in Q4 Earnings?
by Zacks Equity Research
Edward Lifesciences Corp. (EW) is scheduled to report fourth-quarter and full-year 2016 earnings results after market close on Feb 1, 2017.
Illumina (ILMN) Q4 Earnings: A Beat in Store for the Stock?
by Zacks Equity Research
We expect Illumina Inc (ILMN) to beat expectations when it reports fourth-quarter 2016 results after the closing bell on Jan 31.
Is the Options Market Predicting a Spike in Cempra (CEMP) Stock?
by Zacks Equity Research
Investors in Cempra, Inc. (CEMP) need to pay close attention to the stock based on moves in the options market lately.
Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session
by Zacks Equity Research
Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate
by Zacks Equity Research
Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.
Why These 3 Healthcare Stocks Lost Half Their Value in November
by Supriyo Bose
As the equity market braced itself for the Trump era, some healthcare stocks felt the tremors of his ensuing policy reforms and declined significantly in November.